2025-03-12 19:07:16
Latest Post
W S Industries India Ltd's subsidiary to acquire 54.89 acres land for Rs. 46.66 crores
IKS Health wins Top Honors in 2025 Black Book Survey in New AI-Driven RCM Category
Mipco Seamless Rings Gujarat Ltd approves shifting of registered office
Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
REC Limited inaugurates REC Experience Center
Stock Report
Suven Life Sciences Ltd Q4 FY24 consolidated loss at Rs. 26.54 crores
Posted On : 2024-05-06 21:17:28( TIMEZONE : IST )
Suven Life Sciences Limited has reported Consolidated financial results for the period ended March 31, 2024.
Financial Results (Q4 FY2024) - QoQ Comparison
The company has reported total income of Rs. 6.6683 crores during the period ended March 31, 2024 as compared to Rs. 8.5164 crores during the period ended December 31, 2023.
The company has posted net profit / (loss) of Rs. -26.5407 crores for the period ended March 31, 2024 as against net profit / (loss) of Rs. -41.7649 crores for the period ended December 31, 2023.
The company has reported EPS of Rs. -1.22 for the period ended March 31, 2024 as compared to Rs. -1.92 for the period ended December 31, 2023.
| Financials | Q4 FY2024 | Q3 FY2024 | % Change |
| Total Income | ₹ 6.6683 crs | ₹8.5164 crs |  -21.70% |
| Net Profit | ₹-26.5407 crs | ₹-41.7649 crs |  36.45% |
| EPS | ₹-1.22 | ₹-1.92 | 36.46% |
Financial Results (Q4 FY2024) - YoY Comparison
The company has reported total income of Rs. 6.6683 crores during the period ended March 31, 2024 as compared to Rs.8.2133 crores during the period ended March 31, 2023.
The company has posted net profit / (loss) of Rs.-26.5407 crores for the period ended March 31, 2024 as against net profit / (loss) of Rs.-27.6449 crores for the period ended March 31, 2023.
The company has reported EPS of Rs.-1.22 for the period ended March 31, 2024 as compared to Rs.-1.17 for the period ended March 31, 2023.
| Financials | Q4 FY2024 | Q4 FY2023 | % Change |
| Total Income | ₹ 6.6683 crs | ₹8.2133 crs | -18.81% |
| Net Profit | ₹-26.5407 crs | ₹-27.6449 crs | 3.99% |
| EPS | ₹-1.22 | ₹-1.17 |  4.27% |
Financial Results (Year Ended FY2024) - YoY Comparison
The company has reported total income of Rs.32.8229 crores during the Financial Year ended March 31, 2024 as compared to Rs.21.9882 crores during the Financial Year ended March 31, 2023.
The company has posted net profit / (loss) of Rs.-105.0763 crores for the Financial Year ended March 31, 2024 as against net profit / (loss) of Rs.-118.2678 crores for the Financial Year ended March 31, 2023.
The company has reported EPS of Rs.-4.82 for the Financial Year ended March 31, 2024 as compared to Rs.-6.63 for the Financial Year ended March 31, 2023.
| Financials | Year Ended FY2024 | Year Ended FY2023 | % Change |
| Total Income | ₹32.8229 crs | ₹21.9882 crs |  49.28% |
| Net Profit | ₹-105.0763 crs | ₹-118.2678 crs | 11.15% |
| EPS | ₹-4.82 | ₹-6.63 | 27.30% |
Shares of Suven Life Sciences Limited was last trading in BSE at Rs. 111.65 as compared to the previous close of Rs. 113.45. The total number of shares traded during the day was 29960 in over 739 trades.
The stock hit an intraday high of Rs. 114.05 and intraday low of 111.00. The net turnover during the day was Rs. 3386234.00.
